CHF 36.12
(0.94%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 77 Million USD | -90.18% |
2022 | 784.05 Million USD | -5.35% |
2021 | 828.36 Million USD | 102.53% |
2020 | 409.01 Million USD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | 75 Million USD | 212.87% |
2024 Q2 | 75 Million USD | 0.0% |
2023 Q3 | -79 Million USD | -175.12% |
2023 Q1 | 107.48 Million USD | -43.13% |
2023 FY | 77 Million USD | -90.18% |
2023 Q2 | 105.16 Million USD | -2.16% |
2023 Q4 | -66.44 Million USD | 15.89% |
2022 Q1 | 217.15 Million USD | 0.0% |
2022 FY | 784.05 Million USD | -5.35% |
2022 Q4 | 189 Million USD | 1.35% |
2022 Q3 | 186.48 Million USD | -16.87% |
2022 Q2 | 224.33 Million USD | 3.31% |
2021 FY | 828.36 Million USD | 102.53% |
2020 FY | 409.01 Million USD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Relief Therapeutics Holding AG | -98.18 Million CHF | 178.427% |
Tecan Group AG | 132.07 Million CHF | 41.7% |
Santhera Pharmaceuticals Holding AG | 54.78 Million CHF | -40.557% |
Basilea Pharmaceutica AG | 10.45 Million CHF | -636.772% |
Bachem Holding AG | 111.85 Million CHF | 31.163% |
Siegfried Holding AG | 112.77 Million CHF | 31.722% |
Molecular Partners AG | -61.98 Million CHF | 224.226% |